Inhaled selective pulmonary vasodilators

International Anesthesiology Clinics

Volumn 43, Issue 2, 2005, Pages 101-114

  Augoustides, John G ^a   Ochroch, E Andrew ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BOSENTAN; CYCLIC AMP; CYCLIC GMP; ENDOTHELIN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; MILRINONE; NESIRITIDE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; SITAXSENTAN; VASODILATOR AGENT; VASOPRESSIN;

ARTIFICIAL VENTILATION; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DIASTOLIC BLOOD PRESSURE; DRUG COST; HEART ASSIST DEVICE; HEART LEFT ATRIUM PRESSURE; HEART OUTPUT; HEART RIGHT VENTRICLE FUNCTION; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MEDICAL NEBULIZER; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SYRINGE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; HUMANS; HYPERTENSION, PULMONARY; INJECTIONS, INTRAVENOUS; VASODILATOR AGENTS;

EID: 17644367474     PISSN: 00205907     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aia.0000157495.63367.2a     Document Type: Review

References (76)

1. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:35S-62S.
2. Fischer LG, Van Aken H, Burkle H. Management of pulmonary hypertension: physiological and pharmacological considerations for anesthesiologists. Anesth Analg. 2003;96:1603-1616.
3. Blaise G, Langleben D, Hubert B. Pulmonary arterial hypertension: pathophysiology and anesthetic approach. Anesthesiology. 2003;99:1415-1432.
4. Steudel W, Hurford W, Zapol W. Inhaled nitric oxide: basic biology and clinical applications. Anesthesiology 1999;91:1090-1121.
5. Maslow A, Regan M, Panzica P, et al. Precardiopulmonary bypass right ventricular function is associated with poor outcome after coronary artery bypass grafting in patients with severe left ventricular systolic dysfunction. Anesth Analg. 2002;95:1507-1518.
6. Fukamachi K, McCarthy PM, Smedira N, et al. Preoperative risk factors for right ventricular failure after implantable left ventricular assist device insertion. Ann Thorac Surg. 1999;68:2181-2184.
7. Augoustides JG, Ochroch EA. Perioperative use of nitric oxide in cardiothoracic anesthesia and intensive care. Prog Anesth. 2001;15:115-124.
8. Augoustides JG, Ochroch EA. Perioperative management of pulmonary hypertension in cardiothoracic anesthesia and intensive care: beyond nitric oxide. Prog Anesth. 2004; 18:35-48.
9. Lowson SM. Inhaled alternatives to nitric oxide. Anesthesiology. 2002;96:1504-1513.
10. Rubin IJ. Primary pulmonary hypertension. N Engl J Med. 1997;336:111-117.
11. Augoustides JG, Mancini DJ. Postoperative care of the adult cardiac surgical patient. Prog Anesth. 2002;16:99-112.
12. Augoustides JG, Weiss SJ, Pochettino A. Hemodynamic monitoring of the postoperative adult cardiac surgical patient. Semin Thorac Cardiovasc Surg. 2000;12:309-315.
13. Chambers CE, Skeehan TM, Hensley FA. The cardiac catheterization laboratory: diagnostic and therapeutic procedures in the adult patient. In: Kaplan JA, Reich DL, Konstadt SN, eds. Cardiac Anesthesia. Philadelphia: WB Saunders; 1999:41-94.
14. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversal of central shunt. BMJ. 1958;2:701-709.
15. McIntyre KM, Sasahara AA. The hemodynamic response to pulmonary embolism in patients without prior cardiopulmonary disease. Am J Cardiol. 1971;28:288-294.
16. Marcus JT, Vonk NA, Roeleveld RJ, et al. Impaired left ventricular filling due to right ventricular pressure overload in primary pulmonary hypertension: noninvasive monitoring using MRI. Chest. 2001;119:1761-1765.
17. Semigran MJ, Cockrill BA, Kacmarek R, et al. Hemodynamic effects of inhaled nitric oxide in heart failure. J Am Coll Cardiol. 1994;24:982-988.
18. Loh E, Stamler JS, Hare JM, et al. Cardiovascular effects-of inhaled nitric oxide in patients with left ventricular dysfunction; Circulation. 1994;90:2780-2785.
19. Miller O, Tang S, Keech A, et al. Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. Lancet. 1995;346:51-52.
20. Samama CK, Diaby M, Fellahi JL, et al. Inhibition of platelet aggregation by inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesthesiology. 1995;83: 56-65.
21. Lowson SM, Hassan HM, Rich GF. The effect of nitric oxide on platelets when delivered to the cardiopulmonary bypass circuit. Anesth Analg. 1999;89:1360-1365.
22. Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. Am J Cardiol. 1995;75: 3A-10A.
23. Lowson SM, Doctor A, Walsh BK, et al. Inhaled prostacyclin for the treatment of pulmonary hypertension after cardiac surgery. Crit Care Med. 2002;30:2762-2764.
24. Peacock AJ. Primary pulmonary hypertension. Thorax. 1999;54:1107-1118.
25. Cremona G, Higenbottam T. Role of prostacyclin in the treatment of primary pulmonary hypertension. Am J Cardiol. 1995;75:67A-71A.
26. Zwissler B, Weite M, Messmer K. Effects of inhaled prostacyclin as compared to inhaled nitric oxide on right ventricular performance in hypoxic pulmonary vasoconstriction. J Cardiothorac Vasc Anesth. 1995;9:283-289.
27. Max M, Kublen R, Dembinski R, et al. Effect of aerosolized prostacyclin and inhaled nitric oxide on experimental hypoxic pulmonary hypertension. Intensive Care Med. 1999;25:1147-1154.
28. Booke M, Bradford D, Hinder F, et al. Effects of inhaled nitric oxide and nebulized prostacyclin on hypoxic pulmonary vasoconstriction in anesthetized sheep. Crit Care Med. 1996;24:1841-1848.
29. Hill L, Pearl R. Combined inhaled nitric oxide and inhaled prostacyclin during experimental chronic pulmonary hypertension. J Appl Physiol. 1999;86:1160-1164.
30. Mikhail G, Gibbs S, Richardson G, et al. An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension. Eur Heart J. 1997;18: 1499-1504.
31. Webb S, Stott S, van Heerden P. The use of inhaled aerosolized prostacyclin in the treatment of pulmonary hypertension secondary to pulmonary embolism. Intensive Care Med. 1996;22:353-355.
32. Haraldsson A, Kielr-Jensen N, Nathorst-Westfelt U, et al. Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. Chest. 1998;114:780-786.
33. Eichelbronner O, Reinelt H, Wiedeck H, et al. Aerosolized prostacyclin and inhaled nitric oxide in septic shock; different effects on splanchnic oxygenation. Intensive Care Med. 1996;22:880-887.
34. Haraldsson A, Kieler-Jensen N, Ricksten S. Inhaled prostacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplantation. J Cardiothorac Vasc Anesth. 1996;10:864-868.
35. 2 for acute pulmonary hypertension and right ventricular failure. Anesth Analg. 2000;91:291-295.
36. Della Rocca G, Coccia C, Costa M, et al. Inhaled aerosolized prostacyclin and pulmonary hypertension during anesthesia for lung transplantation. Transplant Proc. 2001;33: 1634-1636.
37. Della Rocca G, Coccia C, Pompei L, et al. Hemodynamic and oxygenation changes of combined therapy with inhaled nitric oxide and inhaled aerosolized prostacyclin. J Cardiothorac Vasc Anesth. 2001;15:224-227.
38. Walmrath D, Schneider T, Schermuly R, et al. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med. 1996;153:991-996.
39. Zwissler B, Kemming G, Habler O, et al. Inhaled prostacyclin versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med. 1996;154:1671-1677.
40. Augoustides JGT, Gulp K, Smith S. Rebound pulmonary hypertension and cardiogenic shock after withdrawal of inhaled prostacyclin. Anesthesiology. 2004;100:1023-1025.
41. Olschewski H, Walmrath D, Schermuly R, et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med. 1996;124:820-824.
42. Hoeper M, Olschewski H, Ghofrani H, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. J Am Coll Cardiol. 2000;35:176-182.
43. Grant S, Goa K. Iloprost: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischemia, and extracorporeal circulation procedures. Drugs. 1999;43:889-924.
44. Rex S, Busch T, Vettelschoss M, et al. Intraoperative management of severe pulmonary hypertension during cardiac surgery with inhaled iloprost. Anesthesiology. 2003;99: 745-747.
45. Muller M, Scholz S, Kwapisz M, et al. Use of inhaled iloprost in a case of pulmonary hypertension during pediatric congenital heart surgery. Anesthesiology. 2003;99:743-744.
46. 1: a new therapy for refractory right heart failure and pulmonary hypertension after mitral valve replacement. J Thorac Cardiovasc Surg. 1985;89:567-572.
47. 1_an effective treatment of right heart failure after orthotopic heart transplantation. J Heart Transplant. 1987;6:348-351.
48. 1 and nitroglycerin reduce pulmonary capillary pressure but worsen ventilation-perfusion distribution in patients with the adult respiratory distress syndrome. Anesthesiology. 1989;70:601-606.
49. Kleen M, Habler O, Hofstetter C, et al. Efficacy of inhaled prostanoids in experimental pulmonary hypertension. Crit Care Med. 1998;26:1103-1109.
50. 1 and nitric oxide inhalation in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 1998;157:1743-1747.
51. Sapienza MA, Kharitonov SA, Horvath I, et al. Effect of inhaled L-arginine on exhaled nitric oxide in normal and asthmatic subjects. Thorax. 1998;53:172-175.
52. Chambers DC, Ayres JG. Effect of nebulised L- and D-arginine on exhaled nitric oxide in steroid naive asthma. Thorax. 2001;56:602-606.
53. Schutte H, Grimminger F, Otterbein J, et al. Efficacy of aerosolized nitric oxide donor drugs to achieve sustained pulmonary vasodilation. J Pharmacol Exp Ther 1997;282: 985-994.
54. Gong F, Shiriashi H, Kikuchi Y, et al. Inhalation of nebulized nitroglycerin in dogs with experimental pulmonary hypertension induced by U46619. Pediatr Int. 2000;42:255-258.
55. Yu X, Saugstad D. Nebulization of sodium nitroprusside in lung-lavaged newborn piglets. Pediatr Res. 1999;45:255-259.
56. Meadow W, Rudinsky B, Bell A, et al. Effects of nebulized nitroprusside on pulmonary and systemic hemodynamics during pulmonary hypertension in piglets. Pediatr Res. 1998;44:181-186.
57. Palhares D, Figueiredo C, Mora A. Endotracheal inhalatory sodium nitroprusside in severely hypoxic newborns. J Perinat Med. 1998;26:219-224.
58. Harraldson A, Kieler-Jensen N, Ricksten S. The additive pulmonary vasodilator effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesth Analg. 2001;93:1439-1445.
59. Atz AM, Lefler AK, Fairbrother DL, et al. Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg. 2002;124:628-629.
60. Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002;105:2398-2403.
61. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology. 1999;91:307-310.
62. Raja GS. Treatment of rebound pulmonary hypertension: why not sildenafil? Anesthesiology. 2004;101:1480.
63. Augoustides JGT. Treatment of rebound pulmonary hypertension: why not sildenafil (in reply)? Anesthesiology. 2004;101:1480.
64. Radermacher P, Santak B, Wust H, et al. Prostacyclin for the treatment of pulmonary hypertension in adult respiratory distress syndrome: effects on pulmonary capillary pressure and ventilation-perfusion distributions. Anesthesiology. 1990;72:238-244.
65. Keating GM, Goa KL. Nesiritide: a review of its use in acute decompensated heart failure. Drugs. 2003;63:47-70.
66. Moazami N, Damiano R, Bailey MS, et al. Nesiritide (BNP) in the management of postoperative cardiac patients. Ann Thorac Surg. 2003;75:1974-1976.
67. Tann SM, Ikonomidis JS, Uber W, et al. B-natriuretic peptide improves hemodynamics and renal function in heart transplant patients immediately after surgery. Abstract 257, Presented at the 23rd meeting of the International Society of Heart and Lung Transplantation; Vienna, Austria; 2003.
68. Radovancevic B, Vrtovec B, Yazdanbaksh AP, et al. Perioperative use of nesiritide in heart failure patients undergoing implantation of left ventricular assist device. Abstract 391, Presented at the 23rd meeting of the International Society of Heart and Lung Transplantation; Vienna, Austria; 2003.
69. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res. 2004;61:227-237.
70. Clozel M. Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long-term benefit? Ann Med. 2003;35:605-613.
71. Rich S, McLaughlin W. Endothelin receptor blockers in cardiovascular disease. Circulation. 2003;108:2184-2190.
72. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997;95:122-125.
73. Landry DW, Levin HR, Gallant EM, et al. Vasopressin presser hypersensitivity in vasodilatory septic shock. Crit Care Med. 1997;25:1279-1282.
74. Landry DW, Oliver JA. The pathogenesis of septic shock. N Engl J Med. 2001;345:588-595.
75. Holmes CL, Patel BM, Russell JA, et al. Physiology of vasopressin relevant to management of septic shock. Chest. 2001;120:989-1002.
76. Cheung AT, Weiss SJ, Augoustides JGT, et al. Acute effects of intravenous amiodarone loading in cardiac surgical patients. Ann Thorac Surg. 2003;76:535-541.